somatropin

Uses in Children

Somatropin is primarily used to treat children who have growth failure or are significantly shorter than average due to various medical conditions. These include:

• Growth hormone deficiency: When the body does not produce enough natural growth hormone.
• Genetic disorders: Such as Turner syndrome, Noonan syndrome, Prader-Willi syndrome, and SHOX deficiency.
• Chronic kidney disease: To help children with kidney issues reach a more typical height.
• Small for Gestational Age (SGA): For children born smaller than expected who do not catch up in growth by age two to four.
• Idiopathic short stature: For children who are very short for no known medical reason.

Uses in Adults

In adults, somatropin is used to treat conditions where growth hormone levels are insufficient or where the body needs help maintaining muscle mass and nutrient absorption. Common uses include:

• Growth hormone deficiency: This may be a continuation of a childhood deficiency or a new condition caused by pituitary disease, surgery, or radiation.
• Short bowel syndrome: Used in patients who are receiving specialized nutritional support to help the intestines absorb nutrients more effectively.
• HIV-associated wasting: To treat severe weight loss or muscle wasting (cachexia) in people living with HIV or AIDS.

Mechanism of Action

Somatropin is a laboratory-made form of human growth hormone (HGH). It is created using recombinant DNA technology to be identical to the hormone produced by the pituitary gland. Once administered, it acts as a replacement for natural growth hormone in people who do not produce enough on their own.

The medication works by binding to specific growth hormone receptors on the surface of cells. This interaction triggers several biological processes that support growth and development:

• Skeletal Growth: In children, somatropin stimulates the growth plates in long bones, which leads to an increase in height. It also helps increase bone mineral density.
• Cellular Growth: It promotes the growth and division of cells in various organs and tissues, including muscle tissue.
• Metabolic Regulation: Somatropin helps the body manage nutrients. It increases the synthesis of proteins, encourages the breakdown of stored fats for energy, and influences how the body uses carbohydrates.

Role of IGF-1

A significant portion of somatropin's effect is mediated through the production of insulin-like growth factor 1 (IGF-1). When somatropin reaches the liver and other tissues, it signals them to release IGF-1 into the bloodstream. This factor then acts on various parts of the body to further promote growth and metabolic health.

Common Side Effects

• Pain, redness, itching, or swelling at the injection site
• Swelling in the hands, feet, or lower legs
• Muscle or joint pain
• Headache
• Numbness or tingling sensations
• Cold-like symptoms, such as a sore throat, sneezing, or runny nose

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Vision and brain pressure: Changes in vision, severe headaches, nausea, or vomiting.
• Blood sugar changes: Increased thirst, frequent urination, extreme hunger, or fruity breath odor.
• Pancreas issues: Severe pain in the upper stomach that may spread to the back.
• Bone and joint problems: Limping or pain in the hip or knee.
• Skin changes: New moles or changes in the size, shape, or color of existing moles.
• Breathing problems: New or worsening snoring, gasping, or difficulty breathing during sleep (especially in patients with Prader-Willi syndrome).
• Allergic reactions: Severe rash, hives, or swelling of the face, lips, or throat.
• Adrenal gland issues: Extreme tiredness, dizziness, or weight loss.

Contraindications

Somatropin is contraindicated in individuals with certain medical conditions, including:

• Active malignancy or cancer.
• Acute critical illness resulting from complications of open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure.
• Severe obesity or severe respiratory impairment in patients with Prader-Willi syndrome.
• Active proliferative or severe non-proliferative diabetic retinopathy.
• Closed epiphyses, which occurs when the growth plates in the bones have already fused.

Major Warnings

Increased Mortality: An increased risk of death has been reported in patients with acute critical illness. Treatment is typically discontinued if these conditions develop during therapy.

Malignancy: There is a potential risk of tumor growth or recurrence. Survivors of childhood cancer who were treated with radiation may have an increased risk of developing new tumors, particularly in the brain. Healthcare providers monitor for new skin lesions or changes in existing moles.

Glucose Intolerance and Diabetes: Somatropin can reduce insulin sensitivity, which may lead to high blood sugar or the development of type 2 diabetes. Patients with existing diabetes may require adjustments to their medication dosages.

Intracranial Hypertension: Increased pressure within the skull can occur, causing symptoms such as headaches, nausea, vomiting, and vision changes. Eye exams are usually performed before starting treatment and periodically thereafter.

Prader-Willi Syndrome: There have been reports of sudden death in pediatric patients with Prader-Willi syndrome who have risk factors such as severe obesity, history of upper airway obstruction, or unidentified respiratory infection.

Precautions and Monitoring

Fluid Retention: Treatment may cause swelling, joint pain, or carpal tunnel syndrome. These symptoms are often related to the dose and may resolve if the dosage is adjusted.

Bone and Joint Issues: Children may experience slipped capital femoral epiphysis (the top of the thigh bone slipping out of place) or a worsening of scoliosis during periods of rapid growth. Any new limp or hip and knee pain requires medical evaluation.

Pancreatitis: Severe abdominal pain may indicate pancreatitis, which has been reported in patients using somatropin. This risk may be higher in children than in adults.

Hypothyroidism: Growth hormone therapy may unmask or worsen hypothyroidism. Periodic thyroid function tests are often necessary to ensure the medication remains effective.

Injection Site Reactions: To prevent the loss of fat tissue (lipoatrophy) or localized inflammation, the site of the injection is typically rotated daily.

Pregnancy

It is not known if somatropin can harm an unborn baby. There have not been enough well-controlled studies in pregnant women to determine the safety of this medication during pregnancy. While animal studies have been conducted, they do not always predict how a human pregnancy will be affected.

If you are pregnant or plan to become pregnant, talk with your doctor. They can help you decide if the potential benefits of using somatropin outweigh the potential risks to the pregnancy.

Breastfeeding

It is not known if somatropin passes into breast milk or if it could affect a nursing baby. Because many medications are excreted in human milk, caution is recommended. Discuss your breastfeeding plans with your healthcare provider to determine the safest approach for you and your infant while using this medication.

Available Dosage Forms

Somatropin is administered by subcutaneous injection. It is available in the following formats:

• Lyophilized powder: This form comes in vials or cartridges and must be reconstituted with a sterile diluent before use.
• Pre-filled pens and cartridges: These may contain a pre-mixed liquid solution or a dual-chamber system that mixes the powder and liquid automatically.

Strengths

The concentration and total amount of medication vary widely depending on the specific brand and delivery system used. Common strengths range from small multi-dose vials to larger capacity pens designed for multiple weeks of treatment. Patients should follow the specific instructions provided with their prescribed brand, as preparation and storage requirements differ between products.

FDA Approval and Indications

Somatropin is a recombinant human growth hormone that has been FDA-approved since the 1980s. It is indicated for the treatment of growth failure in pediatric patients due to several conditions, including growth hormone deficiency, Turner syndrome, Noonan syndrome, Prader-Willi syndrome, and being born small for gestational age with no catch-up growth by age two. It is also approved for children with idiopathic short stature and SHOX deficiency.

In adults, somatropin is approved to treat growth hormone deficiency that began in either childhood or adulthood. Specific formulations are also approved for the treatment of short bowel syndrome and HIV-associated wasting or cachexia.

Safety Communications and Reviews

The FDA has conducted safety reviews regarding the long-term use of somatropin. One major review focused on data from a French study (the SAGhE study), which suggested a potential increased risk of death in individuals who were treated with recombinant human growth hormone during childhood. After evaluating the study results and other available data, the FDA concluded that the evidence was inconclusive. The agency continues to recommend that somatropin be prescribed only for its approved indications and at recommended dosages.

Regulatory Contraindications

FDA-approved labeling for somatropin includes several contraindications. The medication should not be used in patients with:

• Acute critical illness resulting from certain types of major surgery, multiple accidental trauma, or acute respiratory failure.
• Active malignancy (cancer).
• Active proliferative or severe non-proliferative diabetic retinopathy.
• Closed epiphyses (when the growth plates in children have fused).
• Prader-Willi syndrome in patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment.

Somatropin and Body Composition

Somatropin is a recombinant human growth hormone that affects how the body processes nutrients and maintains muscle mass. While it is not approved for general weight loss or the treatment of obesity, it is prescribed for specific medical conditions that involve weight and muscle loss.

HIV-Associated Wasting

Somatropin is used to treat wasting (cachexia) in people with HIV. In these cases, the goal of treatment is to increase lean body mass and improve physical functional capacity rather than to reduce body fat for weight management.

Short Bowel Syndrome

This medication is also indicated for the treatment of short bowel syndrome in patients who require specialized nutritional support. It helps the intestines better absorb nutrients, which can help prevent dangerous weight loss and malnutrition in individuals who cannot absorb enough from their diet.

Risks of Misuse for Weight Loss

Somatropin is sometimes used off-label or illegally for weight loss or athletic performance enhancement. There is limited evidence to support its safety or effectiveness for these purposes in healthy individuals. Misusing somatropin can lead to serious health complications, including:

• Swelling in the arms and legs (edema)
• Joint and muscle pain
• Carpal tunnel syndrome
• Increased risk of glucose intolerance or diabetes

Because of these risks, somatropin should only be used under the strict supervision of a healthcare provider for its approved medical indications.